Literature DB >> 27561172

Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.

Pradeep K Singh1, Hao Fan2, Xiuju Jiang2, Lei Shi3, Carl F Nathan2, Gang Lin4.   

Abstract

N,C-capped dipeptides belong to a class of noncovalent proteasome inhibitors. Herein we report that the insertion of a β-amino acid into N,C-capped dipeptides markedly decreases their inhibitory potency against human constitutive proteasome β5c, while maintaining potent inhibitory activity against human immunoproteasome β5i, thereby achieving thousands-fold selectivity for β5i over β5c. Structure-activity relationship studies revealed that β5c does not tolerate the β-amino acid based dipeptidomimetics as does β5i. In vitro, one such compound was found to inhibit human T cell proliferation. Compounds of this class may have potential as therapeutics for autoimmune and inflammatory diseases with less mechanism-based cytotoxicity than agents that also inhibit the constitutive proteasome.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  T cells; autoimmune; immunosuppression; peptidomimetics; β-amino acids; β5i-selective inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27561172      PMCID: PMC5760267          DOI: 10.1002/cmdc.201600384

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  25 in total

Review 1.  Protein degradation and the generation of MHC class I-presented peptides.

Authors:  Kenneth L Rock; Ian A York; Tomo Saric; Alfred L Goldberg
Journal:  Adv Immunol       Date:  2002       Impact factor: 3.543

2.  Hydroxyureas as noncovalent proteasome inhibitors.

Authors:  Nerea Gallastegui; Philipp Beck; Marcelino Arciniega; Robert Huber; Stefan Hillebrand; Michael Groll
Journal:  Angew Chem Int Ed Engl       Date:  2011-11-21       Impact factor: 15.336

3.  Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

Authors:  Karen Fröhlich; Julia U Holle; Peer M Aries; Wolfgang L Gross; Frank Moosig
Journal:  Ann Rheum Dis       Date:  2010-12-20       Impact factor: 19.103

Review 4.  Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy.

Authors:  A L Goldberg
Journal:  Biochem Soc Trans       Date:  2007-02       Impact factor: 5.407

5.  Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Authors:  Christopher Blackburn; Cynthia Barrett; Jonathan L Blank; Frank J Bruzzese; Nancy Bump; Lawrence R Dick; Paul Fleming; Khristofer Garcia; Paul Hales; Zhigen Hu; Matthew Jones; Jane X Liu; Darshan S Sappal; Michael D Sintchak; Christopher Tsu; Kenneth M Gigstad
Journal:  Bioorg Med Chem Lett       Date:  2010-09-15       Impact factor: 2.823

6.  A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.

Authors:  Gerjan de Bruin; Bo Tao Xin; Marianne Kraus; Mario van der Stelt; Gijsbert A van der Marel; Alexei F Kisselev; Christoph Driessen; Bogdan I Florea; Herman S Overkleeft
Journal:  Angew Chem Int Ed Engl       Date:  2015-10-29       Impact factor: 15.336

7.  Mass-spectrometry-based draft of the human proteome.

Authors:  Mathias Wilhelm; Judith Schlegl; Hannes Hahne; Amin Moghaddas Gholami; Marcus Lieberenz; Mikhail M Savitski; Emanuel Ziegler; Lars Butzmann; Siegfried Gessulat; Harald Marx; Toby Mathieson; Simone Lemeer; Karsten Schnatbaum; Ulf Reimer; Holger Wenschuh; Martin Mollenhauer; Julia Slotta-Huspenina; Joos-Hendrik Boese; Marcus Bantscheff; Anja Gerstmair; Franz Faerber; Bernhard Kuster
Journal:  Nature       Date:  2014-05-29       Impact factor: 49.962

8.  Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine.

Authors:  Christian Dubiella; Regina Baur; Haissi Cui; Eva M Huber; Michael Groll
Journal:  Angew Chem Int Ed Engl       Date:  2015-11-13       Impact factor: 15.336

9.  A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

Authors:  Tony Muchamuel; Michael Basler; Monette A Aujay; Erika Suzuki; Khalid W Kalim; Christoph Lauer; Catherine Sylvain; Eileen R Ring; Jamie Shields; Jing Jiang; Peter Shwonek; Francesco Parlati; Susan D Demo; Mark K Bennett; Christopher J Kirk; Marcus Groettrup
Journal:  Nat Med       Date:  2009-06-14       Impact factor: 53.440

10.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.

Authors:  Gang Lin; Tamutenda Chidawanyika; Christopher Tsu; Thulasi Warrier; Julien Vaubourgeix; Christopher Blackburn; Kenneth Gigstad; Michael Sintchak; Lawrence Dick; Carl Nathan
Journal:  J Am Chem Soc       Date:  2013-06-25       Impact factor: 15.419

View more
  16 in total

1.  Improvement of Asparagine Ethylenediamines as Anti-malarial Plasmodium-Selective Proteasome Inhibitors.

Authors:  Wenhu Zhan; Joseph Visone; Tierra Ouellette; Jacob C Harris; Rong Wang; Hao Zhang; Pradeep K Singh; John Ginn; George Sukenick; Tzu-Tshin Wong; Judith I Okoro; Ryan M Scales; Patrick K Tumwebaze; Philip J Rosenthal; Björn F C Kafsack; Roland A Cooper; Peter T Meinke; Laura A Kirkman; Gang Lin
Journal:  J Med Chem       Date:  2019-06-20       Impact factor: 7.446

2.  Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.

Authors:  Hao-Chi Hsu; Pradeep K Singh; Hao Fan; Rong Wang; George Sukenick; Carl Nathan; Gang Lin; Huilin Li
Journal:  Biochemistry       Date:  2016-12-27       Impact factor: 3.162

3.  Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.

Authors:  Esilida Sula Karreci; Hao Fan; Mayuko Uehara; Albana B Mihali; Pradeep K Singh; Ahmed T Kurdi; Zhabiz Solhjou; Leonardo V Riella; Irene Ghobrial; Teresina Laragione; Sujit Routray; Jean Pierre Assaker; Rong Wang; George Sukenick; Lei Shi; Franck J Barrat; Carl F Nathan; Gang Lin; Jamil Azzi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

4.  A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors.

Authors:  Eva Shannon Schiffrer; Izidor Sosič; Andrej Šterman; Janez Mravljak; Irena Mlinarič Raščan; Stanislav Gobec; Martina Gobec
Journal:  Medchemcomm       Date:  2019-09-13       Impact factor: 3.597

5.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

Review 6.  [Research progress on selective immunoproteasome inhibitors].

Authors:  Limin Kong; Jingyi Lu; Huajian Zhu; Jiankang Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-25

7.  Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.

Authors:  Wenhu Zhan; Pradeep K Singh; Yi Ban; Xiaoping Qing; Marie Dominique Ah Kioon; Hao Fan; Quanju Zhao; Rong Wang; George Sukenick; Jane Salmon; J David Warren; Xiaojing Ma; Franck J Barrat; Carl F Nathan; Gang Lin
Journal:  J Med Chem       Date:  2020-10-23       Impact factor: 8.039

8.  Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.

Authors:  Bruno O Villoutreix; Abdel-Majid Khatib; Yan Cheng; Maria A Miteva; Xavier Maréchal; Joëlle Vidal; Michèle Reboud-Ravaux
Journal:  Oncotarget       Date:  2017-02-07

9.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.

Authors:  Ruda de Luna Almeida Santos; Lin Bai; Pradeep K Singh; Naoka Murakami; Hao Fan; Wenhu Zhan; Yingrong Zhu; Xiuju Jiang; Kaiming Zhang; Jean Pierre Assker; Carl F Nathan; Huilin Li; Jamil Azzi; Gang Lin
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

10.  Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse.

Authors:  Marie Dominique Ah Kioon; Michael Pierides; Tania Pannellini; Gang Lin; Carl F Nathan; Franck J Barrat
Journal:  J Immunol       Date:  2021-03-05       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.